Allogeneic bone marrow transplantation (BMT) for acquired severe aplastic anaemia (SAA) in children. 1989

A Locasciulli, and J Vossen, and A Bacigalupo, and J Hows, and M T VanLint, and E Gluckman, and C Nissen, and S McCann, and M de Planque, and L van'tVeer

The SAA Registry of the EBMT now contains data on 171 children younger than 15 years of age with acquired SAA and undergoing BMT between 1970 and 1988. The overall actuarial survival is 63% at 10 years. In a multivariate Cox analysis, the year of transplant was the most important prognostic factor with a significant advantage for children grafted in 1984-88 (81%) vs 1981-83 (67%) and 1970-80 (41%) (p = 0.02). Cyclosporine A given for GVHD prophylaxis, no treatment before transplant and an interval less than 90 days from diagnosis to BMT were all favourable variables in univariate analysis. As regard to transplant procedures, the better results were obtained using Cyclophosphamide and Cyclosporine A (78%) followed by Cyclophosphamide plus irradiation plus Cyclosporine A (77%). Sex, etiology and the severity of the aplasia had no impact on survival in both uni and multivariate analysis.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D012042 Registries The systems and processes involved in the establishment, support, management, and operation of registers, e.g., disease registers. Parish Registers,Population Register,Parish Register,Population Registers,Register, Parish,Register, Population,Registers, Parish,Registers, Population,Registry
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D003524 Cyclosporins A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection. Cyclosporines
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A Locasciulli, and J Vossen, and A Bacigalupo, and J Hows, and M T VanLint, and E Gluckman, and C Nissen, and S McCann, and M de Planque, and L van'tVeer
January 1991, Bone marrow transplantation,
A Locasciulli, and J Vossen, and A Bacigalupo, and J Hows, and M T VanLint, and E Gluckman, and C Nissen, and S McCann, and M de Planque, and L van'tVeer
December 1989, Bone marrow transplantation,
A Locasciulli, and J Vossen, and A Bacigalupo, and J Hows, and M T VanLint, and E Gluckman, and C Nissen, and S McCann, and M de Planque, and L van'tVeer
October 1988, British journal of haematology,
A Locasciulli, and J Vossen, and A Bacigalupo, and J Hows, and M T VanLint, and E Gluckman, and C Nissen, and S McCann, and M de Planque, and L van'tVeer
January 1987, Beitrage zu Infusionstherapie und klinische Ernahrung,
A Locasciulli, and J Vossen, and A Bacigalupo, and J Hows, and M T VanLint, and E Gluckman, and C Nissen, and S McCann, and M de Planque, and L van'tVeer
January 1979, Clinical and laboratory haematology,
A Locasciulli, and J Vossen, and A Bacigalupo, and J Hows, and M T VanLint, and E Gluckman, and C Nissen, and S McCann, and M de Planque, and L van'tVeer
April 1997, The Journal of the Association of Physicians of India,
A Locasciulli, and J Vossen, and A Bacigalupo, and J Hows, and M T VanLint, and E Gluckman, and C Nissen, and S McCann, and M de Planque, and L van'tVeer
July 2012, British journal of haematology,
A Locasciulli, and J Vossen, and A Bacigalupo, and J Hows, and M T VanLint, and E Gluckman, and C Nissen, and S McCann, and M de Planque, and L van'tVeer
January 1989, Folia haematologica (Leipzig, Germany : 1928),
A Locasciulli, and J Vossen, and A Bacigalupo, and J Hows, and M T VanLint, and E Gluckman, and C Nissen, and S McCann, and M de Planque, and L van'tVeer
May 1987, Blut,
A Locasciulli, and J Vossen, and A Bacigalupo, and J Hows, and M T VanLint, and E Gluckman, and C Nissen, and S McCann, and M de Planque, and L van'tVeer
February 1980, The New Zealand medical journal,
Copied contents to your clipboard!